Back to Agenda
Enhancing the Integration of Patient Experience in Assessing Treatment Tolerability
Session Chair(s)
Maria Paula Bautista Acelas, MSc
Scientific Project Manager
DIA, United States
Join us for an engaging discussion on an ongoing DIA study on enhancing the integration of tolerability patient experience data into immune-oncology clinical trials. This session will explore the study’s efforts to address regulatory requirements for the collection of core tolerability patient experience data and the need for a comprehensive, multidimensional approach to assessing tolerability in cancer treatments. With a multistakeholder focus, the study aims to define tolerability more holistically by incorporating treatment-related factors, convenience, and patient beliefs. Learn about the study’s progress, next steps, and its potential to align with regulatory needs while addressing real-world patient concerns.
Learning Objective : Understand the significance of advancing patient-centric tolerability measurement in immune-oncology trials to enhance patient outcomes; Gain insights into the ongoing study and future steps aimed at addressing the real-world needs of patients through a multistakeholder framework.
Speaker(s)
Moderator
Rohini Sen, PhD, MS
AbbVie, United States
Director, HEOR
Unlocking Insights: Progress and Key Findings from the Tolerability Study
Ryan Murphy, PhD
ICON, United States
Associate Outcomes Researcher
Panelist
Representative Invited
FDA, United States
Panelist
Catherine Coulouvrat, DrMed
Sanofi, France
Head of Health Value Translation
Panelist
Lia Ridout
N/A, United States
Patient Advocate
Have an account?